AstraZenca has entered into a settlement agreement with Accord Health and Intas Pharmaceuticals to prevent the sale of generic copies of its anti-psychotic drug Seroquel XR in the US.

The company has granted Accord a licence to enter the US market with its version of the drug on November 1 2016, or earlier, depending upon certain circumstances.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The news follows last week’s announcement that AZ had won its fight to prevent Handa Pharmaceuticals from entering the market with its copy of the extended-release pill for the treatment of schizophrenia until 2016.

The news does not resolve patent battles with other generic drugmakers.

Seroquel will lose patent protection next year but AZ is trying to switch patients over to the newer version (Seroquel XR) ahead of the arrival of generic forms of basic Seroquel.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now